Business Context and Reporting Period
This Form 8-K filing by AcelRx Pharmaceuticals, Inc. (ACRX) was submitted on December 3, 2021, reporting an event that occurred on December 2, 2021. The registrant is a Delaware corporation with its principal executive offices in Hayward, California, and its common stock trades on The Nasdaq Global Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance regarding stock listing standards rather than financial performance.
Material Changes
On December 2, 2021, the Company received written notice from Nasdaq stating it is not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1). The deficiency exists because the closing bid price of the Company's common stock has remained below $1.00 per share for 30 consecutive business days.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has 180 calendar days (until May 31, 2022) to regain compliance. To do so, the closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days.
- Delisting Risk: If the Company fails to regain compliance within the initial 180-day period, it may be eligible for an additional 180-day compliance period if it meets other listing standards for The Nasdaq Capital Market. Failure to cure the deficiency could result in delisting.
- Management Action: The Company intends to actively monitor the closing bid price and evaluate available options, including a potential reverse stock split, to regain compliance.
- Current Status: The notice does not impact the listing of the Company's common stock on The Nasdaq Global Market at this time.
Investor Verification Checklist
- Verify the current closing bid price of ACRX common stock to assess proximity to the $1.00 threshold.
- Monitor the Company's announcements regarding the potential implementation of a reverse stock split.
- Track the number of consecutive business days the stock trades above $1.00 to determine if the 10-day compliance window is met before May 31, 2022.
- Review future filings for updates on the Company's eligibility for a second 180-day compliance period if the initial deadline is missed.